

Flu Kit Booklet 2019

References

1. Huang Q. Key findings - SHIVERS. 2016 New Zealand Influenza Symposium; Wellington, New Zealand; 2016.
2. Ministry of Health. Immunisation Handbook 2017 [Internet]. 2nd ed. Wellington: Ministry of Health; 2017 [March 2018; cited 2019 January 8]. Available from: <https://www.health.govt.nz/publication/immunisation-handbook-2017>
3. Australasian Society of Clinical Immunology and Allergy. Vaccination of the egg-allergic individual. Sydney: Australasian Society of Clinical Immunology and Allergy; 2017.
4. Medsafe. Data sheet – Influvac Tetra [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2017 [updated 2018 November 8; cited 2019 January 7]. Available from: <https://medsafe.govt.nz/profs/Datasheet/i/InfluvacTetrainj2019.pdf>
5. Therapeutic Goods Administration. Fluarix Tetra product information [Internet]. Australian Capital Territory: Therapeutic Goods Administration; 2013 [updated 2018 December 7; cited 2018 December 28]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-02216-1&d=201903101016933>
6. Bresee J, Fry A, Sambhara S, Cos N. Inactivated influenza vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2018. p. 456-88.
7. Centers for Disease Control and Prevention. Influenza (Flu): Influenza signs and symptoms and the role of laboratory diagnostics [Internet]. Atlanta: Centers for Disease Control and Prevention; 2016 [updated 2016 October 26; cited 2018 December 10]. Available from: <https://www.cdc.gov/flu/professionals/diagnosis/labrolesprocedures.htm>
8. Ministry of Health. Communicable disease control manual 2012 (updated November 2018). Wellington: Ministry of Health; 2012.
9. Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. *Vaccine*. 2018;36(23):3199-207.
10. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, et al. Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community. *Proc Natl Acad Sci U S A*. 2018;115(5):1081-6.
11. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: A review of volunteer challenge studies. *Am J Epidemiol*. 2008;167(7):775-85.
12. Huang Y, Zaas AK, Rao A, Dobigeon N, Woolf PJ, Veldman T, et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. *PLoS Genet*. 2011;7(8):e1002234.
13. Jutel A, Baker MG, Stanley J, Huang QS, Bandaranayake D. Self-diagnosis of influenza during a pandemic: A cross-sectional survey. *BMJ Open*. 2011;1(2):e000234.
14. Huang QS, Lopez L, Wood T, Newbern C, for the Institute of Environmental Science and Research Ltd (ESR). Recommendation for seasonal influenza vaccine composition for New Zealand 2018. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2017.
15. World Health Organization. Vaccines against influenza WHO position paper – November 2012. *Wkly Epidemiol Rec*. 2012;47(87):461-76.
16. Ministry of Health. Ministry of Health position statement – addressing influenza immunisation of healthcare workers – March 2018 [Internet]. Wellington: Ministry of Health; 2018 [cited 2018 December 20]. Available from: https://www.health.govt.nz/system/files/documents/pages/2018_dhb_workforce_influenza_immunisation_vaccination_rat es_final.docx
17. Lietz J, Westermann C, Nienhaus A, Schablon A. The occupational risk of influenza A (H1N1) infection among healthcare personnel during the 2009 pandemic: A systematic review and meta-analysis of observational studies. *PLoS One*. 2016;11(8):e0162061.
18. Ahmed F, Lindley MC, Allred N, Weinbaum CM, Grohskopf L. Effect of influenza vaccination of healthcare personnel on morbidity and mortality among patients: Systematic review and grading of evidence. *Clin Infect Dis*. 2014;58(1):50-7.
19. Dolan GP, Harris RC, Clarkson M, Sokal R, Morgan G, Mukaigawara M, et al. Vaccination of healthcare workers to protect patients at increased risk of acute respiratory disease: Summary of a systematic review. *Influenza Other Respir Viruses*. 2013;7(S2):93-6.
20. Riphagen-Dalhuisen J, Burgerhof J, Frijstein G, van der Geest-Blankert A, Danhof-Pont M, de Jager H, et al. Hospital-based cluster randomised controlled trial to assess effects of a multi-faceted programme on influenza vaccine coverage among hospital healthcare workers and nosocomial influenza in the Netherlands, 2009 to 2011. *Euro Surveill*. 2013;18(26):pii=20512.
21. Ministry of Health. 2018 DHB Health Care Worker Influenza Immunisation Coverage [Internet]. Wellington: Ministry of Health; 2018 [cited 2018 December 20]. Available from: https://www.health.govt.nz/system/files/documents/pages/2018_dhb_workforce_influenza_immunisation_vaccination_rat es_final.docx
22. Kunzel W, Engelmann H, D'Hondt E. Immune response to influenza vaccination. *Lancet*. 1994;343(8890):173.
23. Zuckerman M, Cox RJ, Taylor J, Wood JG, Haaheim L, Oxford J. Rapid immune response to influenza vaccination. *Lancet*. 1993;342(8879):113.

24. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season. *Wkly Epidemiol Recc.* 2018;93(42):553-76.
25. Ministry of Health. Health and Disability Services Eligibility Direction 2011 [Internet]. Wellington: Ministry of Health; 2011 [cited 2018 December 10]. Available from: <https://www.health.govt.nz/new-zealand-health-system/eligibility-publicly-funded-health-services/eligibility-direction>
26. Ministry of Health. Section 88 Primary Maternity Services Notice 2007 [Internet]. Wellington: Ministry of Health; 2007 [updated 2018 July 1; cited 2018 December 10]. Available from: <https://www.health.govt.nz/publication/section-88-primary-maternity-services-notice-2007>
27. Pharmaceutical Management Agency (PHARMAC). Pharmaceutical schedule [Internet]. Wellington: PHARMAC; 2019. Available from: <https://www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule/>
28. Kuo AM, Brown JN, Clinard V. Effect of influenza vaccination on international normalized ratio during chronic warfarin therapy. *J Clin Pharm Ther.* 2012;37(5):505-9.
29. Stockwell MS, Broder K, LaRussa P, et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. *JAMA Pediatrics.* 2014;168(3):211-9.
30. Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. *Vaccine.* 2011;29(32):5195-202.
31. Socan M, Frelih T, Janet E, Petraš T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. *Vaccine.* 2004;22(23–24):3087-91.
32. Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ. Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly. *Clinical and experimental vaccine research.* 2017;6(1):38-44.
33. Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥ 50 years of age: Results from a phase III, randomized, non-inferiority trial. *Vaccine.* 2017;35(46):6321-8.
34. Australasian Society of Clinical Immunology and Allergy. Sulfite sensitivity. Sydney: Australasian Society of Clinical Immunology and Allergy Inc.; 2014.
35. Medsafe. Data sheet – Fluarix Tetra [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority; 2014 [updated TBA]. Available from: TBA
36. Jefferson T, Di Pietrantonj C, Al-Ansary L, A., Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev.* 2010(2):Art. No.: CD004876.
37. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. *Lancet Infect Dis.* 2012;12(1):36-44.
38. Beyer WEP, Nauta JJP, Palache AM, Giezenman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. *Vaccine.* 2011;29(34):5785-92.
39. van de Witte SV, Nauta J, Giezenman-Smits KM, de Voogd JM. Trivalent inactivated subunit influenza vaccine Influvac: 30-year experience of safety and immunogenicity. *Trials Vaccinol.* 2012;1:42-8.
40. Zuccotti GV, Fabiano V. Influvac, a trivalent inactivated subunit influenza vaccine. *Expert Opin Biol Ther.* 2011;11(1):89-98.
41. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III, randomized trial in adults aged ≥ 18 years. *BMC Infect Dis.* 2013;13:343.
42. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. *Vaccine.* 2013;31(5):770-6.
43. Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. *Vaccine.* 2015;33(46):6149-51.
44. Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. *Vaccine.* 2016;34(35):4092-102.
45. Petousis-Harris H, Poole T, Turner N, Reynolds G. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. *Vaccine.* 2012;30(33):4945-52.
46. Rodriguez Weber MA, Claeys C, Doniz CA, Feng Y, Innis BL, Jain VK, et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. *Pediatr Infect Dis J.* 2014;33(12):1262-9.
47. Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, et al. Immunogenicity and reactogenicity of an inactivated quadrivalent influenza vaccine administered intramuscularly to children 6 to 35 months of age in 2012–2013: A randomized, double-blind, controlled, multicenter, multicountry, clinical trial. *J Pediatric Infect Dis Soc.* 2015;4(3):242-51.
48. Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6–35 months of age during 2013–2014: Results from a phase II randomized trial. *J Pediatric Infect Dis Soc.* 2016;5(2):170-9.

49. Jain VK, Domachowske JB, Wang L, Ofori-Anyinam O, Rodríguez-Weber MA, Leonardi ML, et al. Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a phase III, randomized, controlled trial. *J Pediatr Infect Dis Soc.* 2017;6(1):9-19.
50. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. *Pediatr Infect Dis J.* 2014;33(6):630-6.
51. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol.* 2016;137(3):868-78.
52. Hughes RAC, Cornblath DR. Guillain-Barre syndrome. *Lancet.* 2005;366(9497):1653-66.
53. Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, Ziegler D, Retalliau H, et al. Guillain-Barre syndrome following vaccination in the National Influenza Program, United States, 1976–1977. *Am J Epidemiol.* 1979;110(2):105-23.
54. Arias LHM, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: A meta-analysis. *Vaccine.* 2015;33(31):3773-8.
55. Iqbal S, Li R, Gargiullo P, Vellozzi C. Relationship between Guillain-Barre syndrome, influenza-related hospitalizations, and influenza vaccine coverage. *Vaccine.* 2015;33(17):2045-9.
56. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. *Am J Epidemiol.* 2009;169(3):382-8.
57. Poland GA, Poland CM, Howe CL. Influenza vaccine and Guillain-Barre syndrome: Making informed decisions. *Lancet.* 2013;381(9876):1437-9.
58. Sadleir LG, Scheffer IE. Febrile seizures. *BMJ.* 2007;334(7588):307-11.
59. Ray R, Dos Santos G, Buck PO, Claeys C, Matias G, Innis BL, et al. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. *Hum Vaccin Immunother.* 2017;13(7):1640-52.
60. Ferdinands JM, Fry AM, Reynolds S, Petrie JG, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011–2012 through 2014–2015. *Clin Infect Dis.* 2017;64(5):544-50.
61. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. *Cochrane Database Syst Rev.* 2018(2):Art. No.: CD004879.
62. Turner N, Pierse N, Bissielo A, Huang QS, Radke S, Baker M, et al. Effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2013. *Euro Surveill.* 2014;19(34):20884.
63. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev.* 2018(2):Art. No.: CD001269.
64. Beyer WEP, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus ADME. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. *Vaccine.* 2013;31(50):6030-3.
65. Darvishian M, van den Heuvel ER, Bissielo A, Castilla J, Cohen C, Englund H, et al. Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: An individual participant data meta-analysis of test-negative design case-control studies. *Lancet Respir Med.* 2017;5(3):200-11.
66. Demicheli V, Jefferson T, Di Pietrantonj C, Ferroni E, Thorning S, Thomas Roger E, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev.* 2018(2):Art. No.: CD004876.
67. Andrew MK, Shinde V, Ye L, Hatchette T, Haguinet F, Dos Santos G, et al. The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. *J Infect Dis.* 2017;216(4):405-14.
68. Casado I, Domínguez A, Toledo D, Chamorro J, Force L, Soldevila N, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. *Expert Rev Vaccines.* 2016;15(3):425-32.
69. Mosnier A, Daviaud I, Caini S, Berche H, Mansuy J-M, van der Werf S, et al. Does seasonal vaccination affect the clinical presentation of influenza among the elderly? A cross-sectional analysis in the outpatient setting in France, 2003–2014. *Vaccine.* 2017;35(16):2076-83.
70. MacIntyre CR, Mahimbo A, Moa AM, Barnes M. Influenza vaccine as a coronary intervention for prevention of myocardial infarction. *Heart.* 2016;102(24):1953-6.
71. Heo JY, Song JY, Noh JY, Choi MJ, Yoon JG, Lee SN, et al. Effects of influenza immunization on pneumonia in the elderly. *Hum Vaccin Immunother.* 2018;14(3):744-9.
72. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: A meta-analysis. *JAMA.* 2013;310(16):1711-20.
73. Lee W-J, Chen L-K, Tang G-J, Lan T-Y. The impact of influenza vaccination on hospitalizations and mortality among frail older people. *Journal of the American Medical Directors Association.* 2014;15(4):256-60.
74. Gill TM, Allore HG, Holford TR, Guo Z. Hospitalization, restricted activity, and the development of disability among older persons. *JAMA.* 2004;292(17):2115-24.
75. Brummel NE, Balas MC, Morandi A, Ferrante LE, Gill TM, Ely EW. Understanding and reducing disability in older adults following critical illness. *Crit Care Med.* 2015;43(6):1265-75.
76. Turner N, Pierse N, Bissielo A, QS H, Baker M, Widdowson M-A, et al. The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. *Vaccine.* 2014;32(29):3687-93.

77. Bissielo A, Pierse N, Huang Q, Thompson M, Kelly H, Mishin V, et al. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: Interim estimates. *Euro Surveill.* 2016;21(1):30101.
78. Pierse N, Kelly H, Thompson MG, Bissielo A, Radke S, Huang QS, et al. Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014. *Vaccine.* 2016;34(4):503-9.
79. Huang QS, Jelley L, Bocacao J, Ralston J, Gunn W, Lopez L, et al. Recommendation for seasonal influenza vaccine composition for New Zealand 2019. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2018.
80. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. *Arch Pediatr Adolesc Med.* 2011;165(2):104-11.
81. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med.* 2014;371(10):918-31.
82. Poehling K, Szilagyi P, Staat M, Snively B, Payne D, Bridges C, et al. Impact of maternal immunization on influenza hospitalizations in infants. *Am J Obstet Gynecol.* 2011;204(Suppl 6):S141-8.
83. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: An observational cohort study. *Lancet Infect Dis.* 2011;11(1):23-9.
84. Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu P-J, et al. Influenza vaccine effectiveness against pediatric deaths: 2010–2014. *Pediatrics.* 2017;139(5):e20164244.
85. Blythe C, Macartney K, Hewagama S, Senenayake S, Friedman N, Simpson G, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014: The Influenza Complications Alert Network (FluCAN). *Euro Surveill.* 2016;21(30):30301.
86. Regan AK, de Klerk N, Moore HC, Omer SB, Shellam G, Effler PV. Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: A retrospective cohort study. *Vaccine.* 2016;34(32):3649-56.
87. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: Review of evidence. *Expert Rev Vaccines.* 2017;16(7):723-36.
88. Shinjoh M, Sugaya N, Yamaguchi Y, Iibuchi N, Kamimaki I, Goto A, et al. Inactivated influenza vaccine effectiveness and an analysis of repeated vaccination for children during the 2016/17 season. *Vaccine.* 2018;36(37):5510-8.
89. Bartoszko JJ, McNamara IF, Aras OAZ, Hylton DA, Zhang YB, Malhotra D, et al. Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis. *Vaccine.* 2018;36(24):3434-44.
90. Cheng AC, Macartney KK, Waterer GW, Kotsimbos T, Kelly PM, Blyth CC, et al. Repeated vaccination does not appear to impact upon influenza vaccine effectiveness against hospitalization with confirmed influenza. *Clin Infect Dis.* 2017;64(11):1564-72.
91. Lin H-C, Chiu H-F, Ho S-C, Yang C-Y. Association of influenza vaccination and reduced risk of stroke hospitalization among the elderly: A population-based case-control study. *Int J Environ Res Public Health.* 2014;11(4):3639.
92. Chiang M-H, Wu H-H, Shih C-J, Chen Y-T, Kuo S-C, Chen T-L. Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients. *Am Heart J.* 2017;193:1-7.
93. Fang Y-A, Chen C-I, Liu J-C, Sung L-C. Influenza vaccination reduces hospitalization for heart failure in elderly patients with chronic kidney disease: A population-based cohort study. *Acta Cardiol Sin.* 2016;32(3):290-8.
94. Chen C-I, Kao P-F, Wu M-Y, Fang Y-A, Miser JS, Liu J-C, et al. Influenza vaccination is associated with lower risk of acute coronary syndrome in elderly patients with chronic kidney disease. *Medicine.* 2016;95(5):e2588.
95. Sung L-C, Chen C-I, Fang Y-A, Lai C-H, Hsu Y-P, Cheng T-H, et al. Influenza vaccination reduces hospitalization for acute coronary syndrome in elderly patients with chronic obstructive pulmonary disease: A population-based cohort study. *Vaccine.* 2014;32(30):3843-9.
96. Siriwardena AN, Gwini SM, Coupland CAC. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: Matched case-control study. *Can Med Assoc J.* 2010;182(15):1617-23.
97. Modin D, Jorgensen ME, Gislason G, Jensen JS, Kober L, Claggett B, et al. Influenza vaccine in heart failure: Cumulative number of vaccinations, frequency, timing, and survival: A Danish nationwide cohort study. *Circulation.* Forthcoming 2018.
98. Cruzeta APS, Schneider IJC, Traebert J. Impact of seasonality and annual immunization of elderly people upon influenza-related hospitalization rates. *Int J Infect Dis.* 2013;17(12):e1194-e7.
99. International Federation on Ageing. Adult vaccination: A public health priority expert meeting report [Internet]. Toronto: International Federation on Ageing; 2017 [cited 2019 January 5]. Available from: <https://www.ifa-fiv.org/wp-content/uploads/2017/11/Final-report-Adult-Vaccination-A-Public-Health-Expert-Meeting.pdf>
100. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. *Nat Immunol.* 2013;14(5):428-36.
101. Loubet P, Loulergue P, Galtier F, Launay O. Seasonal influenza vaccination of high-risk adults. *Expert Rev Vaccines.* 2016;15(12):1507-18.
102. Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, et al. Immunosenescence: Implications for response to infection and vaccination in older people. *Maturitas.* 2015;82(1):50-5.
103. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. *Clin Infect Dis.* 2000;181(3):831-7.

104. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA*. 2003;289(2):179-86.
105. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. *Vaccine*. 2007;25(5):846-55.
106. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: Systematic review and meta-analysis. *BMJ*. 2013;347:f5061.
107. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, et al. The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. *Vaccine*. 2012;30(12):2060-7.
108. Fleming DM, Elliot AJ. The impact of influenza on the health and health care utilisation of elderly people. *Vaccine*. 2005;23(Suppl 1):S1-9.
109. Kuster SP, Tuite AR, Kwong JC, McGeer A, the Toronto Invasive Bacterial Diseases N, Fisman DN. Evaluation of coseasonality of influenza and invasive pneumococcal disease: Results from prospective surveillance. *PLoS Med*. 2011;8(6):e1001042.
110. Barnes M, Heywood AE, Mahimbo A, Rahman B, Newall AT, Macintyre CR. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. *Heart*. 2015;101(21):1738-47.
111. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. *N Engl J Med*. 2018;378(4):345-53.
112. Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, et al. Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes. *CMAJ*. 2016;188(14):E342-E51.
113. Liu J-C, Wang T-J, Sung L-C, Kao P-F, Yang T-Y, Hao W-R, et al. Influenza vaccination reduces hemorrhagic stroke risk in patients with atrial fibrillation: A population-based cohort study. *Int J Cardiol*. 2017;232:315-23.
114. Vasileiou E, Sheikh A, Butler C, El Ferkh K, von Wissmann B, McMenemy J, et al. Effectiveness of influenza vaccines in asthma: A systematic review and meta-analysis. *Clin Infect Dis*. 2017;65(8):1388-95.
115. Barker WH, Borisute H, Cox C. A study of the impact of influenza on the functional status of frail older people. *Arch Intern Med*. 1998;158(6):645-50.
116. Liu IF, Huang C-C, Chan W-L, Huang P-H, Chung C-M, Lin S-J, et al. Effects of annual influenza vaccination on mortality and hospitalization in elderly patients with ischemic heart disease: A nationwide population-based study. *Prev Med*. 2012;54(6):431-3.
117. Huang C-L, Nguyen PA, Kuo P-I, Iqbal U, Hsu Y-HE, Jian W-S. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. *Comput Methods Programs Biomed*. 2013;111(2):507-11.
118. Huang H-H, Chen S-J, Chao T-F, Liu C-J, Chen T-J, Chou P, et al. Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study. *J Microbiol Immunol Infect*. Forthcoming 2017.
119. Torner N, Navas E, Soldevila N, Toledo D, Navarro G, Morillo A, et al. Costs associated with influenza-related hospitalization in the elderly. *Hum Vaccin Immunother*. 2017;13(2):412-6.
120. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy. *J Infect*. 2014;68(4):363-71.
121. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA*. 2004;292(11):1333-40.
122. McElhaney JE, Andrew MK, McNeil SA. Estimating influenza vaccine effectiveness: Evolution of methods to better understand effects of confounding in older adults. *Vaccine*. 2017;35(46):6269-74.
123. Bagshaw SM, Stelfox HT, McDermid RC, Rolfson DB, Tsuyuki RT, Baig N, et al. Association between frailty and short- and long-term outcomes among critically ill patients: A multicentre prospective cohort study. *Can Med Assoc J*. 2014;186(2):E95-E102.
124. Sacanella E, Pérez-Castejón JM, Nicolás JM, Masanés F, Navarro M, Castro P, et al. Functional status and quality of life 12 months after discharge from a medical ICU in healthy elderly patients: A prospective observational study. *Crit Care*. 2011;15(2):R105.
125. Khouli H, Astua, A. , Dombrowski, W. , Ahmad, F. , Homel, P. , Shapiro, J. , Singh, J. , Nallamothu, R. , Mahbub, H. , Eden, E. & Delfiner, J. Changes in health-related quality of life and factors predicting long-term outcomes in older adults admitted to intensive care units. *Crit Care Med*. 2011;39(4):731-7.
126. Sah P, Medlock J, Fitzpatrick MC, Singer BH, Galvani AP. Optimizing the impact of low-efficacy influenza vaccines. *Proc Natl Acad Sci U S A*. 2018;115(20):5151-6.
127. Plans-Rubio P. The vaccination coverage required to establish herd immunity against influenza viruses. *Prev Med*. 2012;55(1):72-7.
128. Kim TH. Seasonal influenza and vaccine herd effect. *Clin Exp Vaccine Res*. 2014;3(2):128-32.
129. Chan TC, Fan-Ngai Hung I, Ka-Hay Luk J, Chu LW, Hon-Wai Chan F. Effectiveness of influenza vaccination in institutionalized older adults: A systematic review. *Journal of the American Medical Directors Association*. 2014;15(3):226 e1-6.
130. Harris J. Influenza occurring in pregnant women: A statistical study of thirteen hundred and fifty cases. *JAMA*. 1919;72(14):978-80.
131. Dodds L, McNeill S, Fell D, Allen V, Coombs A, Scott J, et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. *CMAJ*. 2007;176(4):463-8.

132. Dreier JW, Andersen A-MN, Berg-Beckhoff G. Systematic review and meta-analyses: Fever in pregnancy and health impacts in the offspring. *Pediatrics*. 2014;133(3):e674-88.
133. Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, et al. Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy. *Proc Natl Acad Sci U S A*. 2014;111(40):14506-11.
134. Mosby L, Rasmussen S, Jamieson D. 2009 pandemic influenza A (H1N1) in pregnancy: A systematic review of the literature. *Am J Obstet Gynecol*. 2011;205(1):10-8.
135. Omer SB, Bednarczyk RA, Madhi SA, Klugman KP. Benefits to mother and child of influenza vaccination during pregnancy. *Hum Vaccin Immunother*. 2012;8(1):130-7.
136. Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, et al. The burden of influenza in young children, 2004–2009. *Pediatrics*. 2013;131(2):207-16.
137. Ruf BR, Knuf M. The burden of seasonal and pandemic influenza in infants and children. *Eur J Pediatr*. 2014;173(3):265-76.
138. van Kerkhove MD, Vandemaële KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: A global pooled analysis. *PLoS Med*. 2011;8(7):e1001053.
139. Marshall H, McMillan M, Andrews RM, Macartney K, Edwards K. Vaccines in pregnancy: The dual benefit for pregnant women and infants. *Hum Vaccin Immunother*. 2016;12(4):848-56.
140. Bednarczyk RA, Adjaye-Gbewonyo D, Omer SB. Safety of influenza immunization during pregnancy for the fetus and the neonate. *Am J Obstet Gynecol*. 2012;207(Suppl 3):S38-46.
141. Global Advisory Committee on Vaccine Safety. Safety of immunization during pregnancy: A review of the evidence. Internet. Geneva: World Health Organization; 2014.
142. Nordin JD, Kharbanda EO, Benitez GV, Nichol K, Lipkind H, Naleway A, et al. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. *Obstet Gynecol*. 2013;121(3):519-25.
143. Kharbanda EO, Vazquez-Benitez G, Lipkind H, Naleway A, Lee G, Nordin JD, et al. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. *Obstet Gynecol*. 2013;122(3):659-67.
144. Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal influenza vaccination and risk for congenital malformations: A systematic review and meta-analysis. *Obstet Gynecol*. 2015;126(5):1075-84.
145. Sheffield JS, Greer LG, Rogers VL, Roberts SW, Lytle H, McIntire DD, et al. Effect of influenza vaccination in the first trimester of pregnancy. *Obstet Gynecol*. 2012;120(3):532-7.
146. Regan AK, Moore HC, de Klerk N, Omer SB, Shellam G, Mak DB, et al. Seasonal trivalent influenza vaccination during pregnancy and the incidence of stillbirth: Population-based retrospective cohort study. *Clin Infect Dis*. 2016;62(10):1221-7.
147. Zhang C, Wang X, Liu D, Zhang L, Sun X. A systematic review and meta-analysis of fetal outcomes following the administration of influenza A/H1N1 vaccination during pregnancy. *Int J Gynaecol Obstet*. 2018;141(2):141-50.
148. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: A systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. *Vaccine*. 2015;33(18):2108-17.
149. Bratton KN, Wardle MT, Orenstein WA, Omer SB. Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: A systematic review and meta-analysis. *Clin Infect Dis*. 2015;60(5):e11-9.
150. Chambers CD, Johnson DL, Xu R, Luo YJ, Louik C, Mitchell AA, et al. Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. *Vaccine*. 2016;34(37):4443-9.
151. Zerbo O, Modaresi S, Chan B, Goddard K, Lewis N, Bok K, et al. No association between influenza vaccination during pregnancy and adverse birth outcomes. *Vaccine*. 2017;35(24):3186-90.
152. Branch DW. Physiologic adaptations of pregnancy. *Am J Reprod Immunol*. 1992;28(3-4):120-2.
153. Jamieson D, Theiler R, Rasmussen S. Emerging infections and pregnancy. *Emerg Infect Dis*. 2006;12(11):1638-43.
154. Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. *Horm Behav*. 2012;62(3):263-71.
155. McHugh L, Marshall HS, Perrett KP, Nolan T, Wood N, Lambert SB, et al. The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012–2015: The FluMum Study. *Clin Infect Dis*. 2018:ciy517-ciy.
156. Bithell JF, Draper GJ, Gorbach PD. Association between malignant disease in children and maternal virus infections. *Br Med J*. 1973;1(5855):706.
157. Bennet R, Hamrin J, Wirgart BZ, Ostlund MR, Ortqvist A, Eriksson M. Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998–2014. *Vaccine*. 2016;34(28):3298-302.
158. Litmus Limited. Immunisation for pregnant women: Audience research with pregnant women. Wellington: Ministry of Health; 2015.
159. Henninger ML, Irving SA, Thompson M, Avalos LA, Ball SW, Shifflett P, et al. Factors associated with seasonal influenza vaccination in pregnant women. *J Womens Health*. 2015;24(5):394-402.
160. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: A literature review. *Vaccine*. 2015;33(47):6420-9.
161. Yuen CYS, Tarrant M. Determinants of uptake of influenza vaccination among pregnant women – A systematic review. *Vaccine*. 2014;32(36):4602-13.
162. Meharry PM, Colson ER, Grizas AP, Stiller R, Vázquez M. Reasons why women accept or reject the trivalent inactivated influenza vaccine (TIV) during pregnancy. *Matern Child Health J*. 2013;17(1):156-64.

163. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. *Obstet Gynecol.* 2012;119(3):631-9.
164. Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Altaye M, et al. Influenza immunization in pregnancy – Antibody responses in mothers and infants. *N Engl J Med.* 2010;362(17):1644-6.
165. Benowitz I, Esposito DB, Gracey KD, Shapiro ED, Vazquez M. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. *Clin Infect Dis.* 2010;51(12):1355-61.
166. Jamieson DJ, Kissin DM, Bridges CB, Rasmussen SA. Benefits of influenza vaccination during pregnancy for pregnant women. *Am J Obstet Gynecol.* 2012;207(Suppl 3):S17-20.
167. Nunes MC, Cutland CL, Jones S, et al. Duration of infant protection against influenza illness conferred by maternal immunization: Secondary analysis of a randomized clinical trial. *JAMA Pediatrics.* 2016;170(9):840-7.
168. Shakib JH, Korgenski K, Presson AP, Sheng X, Varner MW, Pavia AT, et al. Influenza in infants born to women vaccinated during pregnancy. *Pediatrics.* 2016;137(6):e20152360.
169. van Santen KL, Bednarczyk RA, Adjaye-Gbewonyo D, Orenstein WA, Davis R, Omer SB. Effectiveness of pneumococcal conjugate vaccine in infants by maternal influenza vaccination status. *Pediatr Infect Dis J.* 2013;32(11):1180-4.
170. The American College of Obstetricians and Gynecologists. Influenza vaccination during pregnancy [Internet]. The American Congress of Obstetricians and Gynecologists; 2018 [updated 2018; cited 2018 December 10]. Available from: <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Influenza-Vaccination-During-Pregnancy>
171. Thompson MG, Kwong JC, Regan AK, Katz MA, Drews SJ, Azziz-Baumgartner E, et al. Influenza vaccine effectiveness in preventing influenza-associated hospitalizations during pregnancy: A multi-country retrospective test negative design study, 2010–2016. *Clin Infect Dis.* Forthcoming 2018:ciy737-ciy.
172. Thompson MG, Li D-K, Shifflett P, Sokolow LZ, Ferber JR, Kurosky S, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: A population-based case-control study during the 2010–2011 and 2011–2012 influenza seasons. *Clin Infect Dis.* 2014;58(4):449-57.
173. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. *J Infect.* 2017;75(5):381-94.
174. Chambers CD, Xu R, Mitchell AA. Commentary on: “Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12”. *Vaccine.* 2017;35(40):5323-4.
175. Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, et al. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010–11 and 2011–12. *Vaccine.* 2017;35(40):5314-22.
176. Sperling SR, Riley EL. Influenza vaccination, pregnancy safety, and risk of early pregnancy loss. *Obstet Gynecol.* 2018;131(5):799-802.
177. Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Jackson L, et al. Infant hospitalizations and mortality after maternal vaccination. *Pediatrics.* 2018;141(3):e20173310.
178. Buchan SA, Hottes TS, Rosella LC, Crowcroft NS, Tran D, Kwong JC. Contribution of influenza viruses to medically attended acute respiratory illnesses in children in high-income countries: A meta-analysis. *Influenza Other Respir Viruses.* 2016;10(6):444-54.
179. Institute of Environmental Science and Research Ltd (ESR). Recommendation for seasonal influenza vaccine composition for New Zealand 2017. Wellington: Institute of Environmental Science and Research Ltd; 2016. Report No.: FW16045.
180. Li-Kim-Moy J, Yin JK, Blyth CC, Kesson A, Booy R, Cheng AC, et al. Influenza hospitalizations in Australian children. *Epidemiol Infect.* 2017;145(7):1451-60.
181. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the United States, 2010–2016. *Pediatrics.* 2018;141(4):e20172918.
182. Heikkinen T, Silvennoinen H, Heinonen S, Vuorinen T. Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children. *Eur J Clin Microbiol Infect Dis.* 2016;35(7):1107-13.
183. Grohskopf L, Sokolow L, Broder K, Walter E, Bresee J, Fry A, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season. *MMWR Recomm Rep.* 2017;66(2):1-20.
184. Public Health England. National flu immunisation programme plan for 2018 to 2019. London: Public Health England; 2018.
185. Gill PJ, Ashdown HF, Wang K, Heneghan C, Roberts NW, Harnden A, et al. Identification of children at risk of influenza-related complications in primary and ambulatory care: A systematic review and meta-analysis. *Lancet Respir Med.* 2015;3(2):139-49.
186. Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naïve 5–8-year-old children. *J Infect Dis.* 2006;194(8):1032-9.
187. Wang S-Y, Liu S-Z, Chu K, Zhao Y, Zhu F-C, Hu Y-M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants ≥ 3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. *Expert Rev Vaccines.* 2017;16(11):1155-69.
188. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: Two open-label, randomised controlled trials. *Lancet.* 2009;374:1339-50.

189. Prymula R, Habib A, Francois N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. *Vaccine*. 2013;31(16):2080-8.
190. Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: A systematic review. *PLoS One*. 2014;9(9):e106629.
191. Pollyea DA, Brown JMY, Horning SJ. Utility of influenza vaccination for oncology patients. *J Clin Oncol*. 2010;28(14):2481-90.
192. Bosaeed M, Kumar D. Seasonal influenza vaccine in immunocompromised persons. *Hum Vaccin Immunother*. 2018;14(6):1311-22.
193. Beck CR, McKenzie BC, Hashim AB, Harris RC, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology. *J Infect Dis*. 2012;206(8):1250-9.
194. Askling HH, Rombo L. Influenza in travellers. *Curr Opin Infect Dis*. 2010;23(5):421-5.
195. Steffen R. Influenza in travelers: Epidemiology, risk, prevention, and control issues. *Curr Infect Dis Rep*. 2010;12(3):181-5.
196. Browne A, St-Onge Ahmad S, Beck CR, Nguyen-Van-Tam JS. The roles of transportation and transportation hubs in the propagation of influenza and coronaviruses: A systematic review. *J Travel Med*. 2016;23(1).
197. Brotherton JML, Delpech VC, Gilbert GL, Hatzi S, Paraskevopoulos PD, McAnulty JM. A large outbreak of influenza A and B on a cruise ship causing widespread morbidity. *Epidemiol Infect*. 2003;130(2):263-71.
198. Miller JM, Tam TWS, Maloney S, Fukuda K, Cox N, Hockin J, et al. Cruise ships: High-risk passengers and the global spread of new influenza viruses. *Clin Infect Dis*. 2000;31(2):433-8.
199. Payne M, Skowronski D, Sabaiduc S, Merrick L, Lowe C. Increase in hospital admissions for severe influenza A/B among travelers on cruise ships to Alaska, 2015. *Emerg Infect Dis*. 2018;24(3):566-8.
200. Gautret P, Soula G, Parola P, Brouqui P. Hajj pilgrims' knowledge about acute respiratory infections. *Emerg Infect Dis*. 2009;15(11):1861.
201. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Internet. Geneva: World Health Organization; 2018.